Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants

Behavioural Brain Research

Volumn 97, Issue 1-2, 1998, Pages 59-68

  Schroeder, Ulrike ^a   Schroeder, Helmut ^a   Darius, Joerg ^a   Grecksch, Gisela ^a   Sabel, Bernhard A ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

3H TCP binding; Controlled release polymer; Hippocampus; Latent inhibition; Pharmacokinetics; Schizophrenia

Indexed keywords

PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA;

ANIMALS; BRAIN; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; EMOTIONS; HALLUCINOGENS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; POLYVINYLS; PSYCHOSES, SUBSTANCE-INDUCED; RATS;

EID: 0032401789     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(98)00027-8     Document Type: Article

References (45)

1. Anscombe F. The disorder of consciousness in schizophrenia. Schizophr Bull. 2:1987;241-260.
2. Balster R.L. The behavioral pharmacology of phencyclidine. Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. 1987;1573-1579 Raven Press, New York.
3. Bogerts B. Recent advances in the neuropathology of schizophrenia. Schizophr Bull. 19(1993):1993;431-445.
4. Carlsson M., Carlsson A. Interactions between the glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
5. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 2:1996;241-253.
6. During M.J., Freese A., Sabel B.A., Saltzman M.W., Deutch A., Roth R.H., Langer R. Controlled release of dopamine from a polymeric brain implant: In vivo characterization. Ann Neurol. 25:1989;351-356.
7. Ellison G. Neuronal degeneration following both competitive and non-competitive NMDA antagonists. Neuroreport. 5:1994;2688-2692.
8. Ellison G. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and antomical models of dementias. Brain Res Rev. 20:1995;250-267.
9. Ellison G., Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport. 5:1993;17-20.
10. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., Peter H.S., Olney J.W. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? Biol Psychiatry. 38:1995;788-796.
11. Feldman HW, Agar MH, Bescher GM. Angel Dust, An Ethnographic Study of PCP Users. Lexington, MA: DC, Heath, 1979.
12. 3H]kainate binding in hippocampus 24 h after PCP. Neurosci Lett. 174:1994;149-153.
13. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
14. Gray N.S., Pilowsky L.S., Gray J.A., Kerwin R.W. Latent inhibition in drug naive schizophrenics: Relationship to duration of illness and dopamine D2 binding using SPECT. Schizophr Bull. 17:1995;95-105.
15. Haik-Crequer KL, Dunbar GL, Sabel BA, Schroeder U. Small drug sample fabrication of controlled release polymers using the microextrusion method. J Neurosci Methods 1998, in press.
16. Han J.S., Gallagher M., Holland P. Hippocampal lesions disrupt decrements but not increments in conditioned stimulus processing. J Neurosci. 15:1995;7323-7329.
17. Jaffe JH. Drug addiction and drug abuse. Gilman A.G., Goodman L.S. The Pharmacological Basis of Therapeutics. 1980;535-607 Macmillan, New York.
18. Javitt D.C., Zukin S.R. Mechanisms of phencyclidine (PCP)-N-methyl-D-aspartate (NMDA) receptor interaction: Implication for schizophrenia. Adv Neuropsych Neuropsychopharmacol. 1:1991;13-19.
19. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
20. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
21. Kesner R.P., Dakis M. Phencyclidine injections into the dorsal hippocampus disrupt long-but not short-term memory within a spatial learning task. Psychopharmacology. 120:1995;203-208.
22. Köhler U., Schröder H., Augustin W., Sabel B.A. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci Lett. 170:1994;99-102.
23. Lillrank S.M., O'Connor W.T., Saransaari P., Ungerstedt U. In vivo effects of local and systemic phencyclidine on the extracellular levels of catecholamines and transmitter amino acids in the dorsolateral striatum of anaestetized rats. Acta Physiol Scand. 150:1994;109-115.
24. Long J.M., Kesner R.P. Phencyclidine impairs temporal order memory for spatial locations in rats. Pharmacol Biochem Behav. 52:1995;645-648.
25. Lubow R.E. Latent inhibition. Psychol Bull. 79:1973;398-407.
26. Lubow R.E., Weiner I., Schlossberg A., Baruch I. Latent inhibition and schizophrenia. Bull Psych Soc. 25:1987;464-467.
27. Mackintosh NJ Stimulus selection: Learning to ignore stimuli that predict no change in reinforcement. Hinde R.A., Stevenson-Hinde J. Constraints on Learning. 1973;175-196 Academic Press, London.
28. Mackintosh N.J. A theory of attention: Variations in the associability of stimuli with reinforcement. Psychol Rev. 82:1975;276-298.
29. Marino A., Florio T., Meucci O., Landolfi E., Grimaldi M., Ventra C., Schettini G. Fipexide improvement of cognitive functions in rat: Behavioural and neurochemical studies. Pharmacol Res. 22:1990;179-187.
30. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia. Br J Pharmacol. 116:1995;2531-2537.
31. Ogawa S., Okuyama S., Araki H., Nakazato A., Otomo S. A rat model of phencyclidine psychosis. Life Sci. 21:1994;1605-1610.
32. Olney J.W. New mechanisms of excitatory transmitter neurotoxicity. J Neural Transm Suppl. 43:1994;47-51.
33. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
34. Olney J.W., Labruyere J., Wang G., Wozniak D., Price M., Sesma M. NMDA antagonist neurotoxicity: Mechanisms and prevention. Science. 254:1991;1515-1518.
35. Pearlson G. Psychiatric and medical syndromes with phencyclidine (PCP) abuse. Johns Hopkins Med J. 148:1980;25-33.
36. Raja S.N., Guyenet P.G. Action of phencyclidine on synaptic transmission in the hippocampus. Brain Res. 236:1982;289-304.
37. Sabel B.A., Dominiak P., Häuser W., During M.J., Freese A. Levodopa delivery from controlled-release polymer matrix: Delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J Pharm Exp Ther. 255:1990;914-922.
38. Sayed Y., Garrison J.M. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs - a review. Psychopharmacol Bull. 19:1983;283-288.
39. Schwegler H., Lipp H.P. Hereditary covariations of neuronal circuitry and behavior: Correlations between the proportions of hippocampal synaptic fields in the regio inferior and two-way avoidance in mice and rats. Behav Brain Res. 5:1983;1-39.
40. Taminga C., Thaker G., Buchanan R., Kirpatrick B., Alphs L., Chase T., Carpenter W. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 49:1992;522-530.
41. Thornberg S.A., Saklad S.S. A review of NMDA receptors and the phencyclidine model of schizophrenia. Pharmacotherapy. 16:1996;82-93.
42. Ulas J., Cotman C. Excitatory amino acid receptors in schizophrenia. Schizophr Bull. 19:1993;105-117.
43. Weiner I., Feldon J. Phencyclidine does not disrupt latent inhibition in rats: Implications for animal models of schizophrenia. Pharmacol Biochem Behav. 42:1991;625-631.
44. Weiner I., Lubow R.E., Feldon J. Chronic amphetamine and latent inhibition. Behav Brain Res. 2:1981;285-286.
45. Zukin S.R., Young A.B., Snyder S.H. γ-Aminobutyric acid binding to receptor binding sites in the central nervous system. Proc Natl Acad Sci USA. 71:1974;4802-4807.